Leonildo Delgado

Boobalan Pacha

Boobalan Pachaiyappan

- Addex Therapeutics completed H1 2025 with **CHF 2.3 million** in cash, providing a cash runway through **mid-2026**, though current cash does not fund the progression of unpartnered programs into the clinic.  **[1574232_2163734_0]** **[1574232_2163734_5]** 
- The company's partner, Indivior, successfully completed IND enabling studies for a GABA B PAM drug candidate for substance use disorders, making Addex eligible for up to **$330 million** in milestones and tiered royalties.  **[1574232_2163734_0]** **[1574232_2163734_1]** **[1574232_2163734_2]** **[1574232_2163734_5]** 
- Addex is advancing its independent GABA B PAM program for chronic cough, having substantially completed preclinical profiling with robust anti-tussive data, and is ready to start IND enabling studies **subject to securing financing**.  **[1574232_2163734_0]** **[1574232_2163734_1]** **[1574232_2163734_4]** **[1574232_2163734_5]** 
- Neuroserx, in which Addex holds a **20% equity interest**, has made excellent progress, completing IND enabling studies for its m4 PAM program and is on track to dose patients this year.  **[1574232_2163734_1]** **[1574232_2163734_5]**

Addex Therapeutics (ADXN)